Physician profile
Corlis Archer Goode
NPI 1437152360
$3,279.94
in general payments reported to CMS, 2019-2025
42 companies · $322 in 2025
The $322 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,151 · 2020: $287 · 2021: $388 · 2022: $429 · 2023: $214 · 2024: $488 · 2025: $322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,025.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,024.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $504.78 | 2019-2024 | Xtandi, Myrbetriq |
| Dendreon Pharmaceuticals LLC | $204.95 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $196.11 | 2019-2025 | |
| Pfizer INC. | $173.16 | 2019-2022 | |
| Rochester Medical Corporation | $155.43 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $149.14 | 2023-2025 | Gemtesa |
| Abbvie INC. | $128.75 | 2023-2025 | Botox |
| Myriad Genetic Laboratories, INC. | $125.13 | 2022-2025 | Myrisk, Prolaris |
| Janssen Biotech, INC. | $123.30 | 2019-2021 | |
| Caldera Medical, INC | $121.00 | 2024 | Desara |
| Boston Scientific Corporation | $111.46 | 2019-2025 | Axonics, Ams 700 |
| Allergan, INC. | $101.44 | 2019-2021 | |
| Urovant Sciences INC | $94.55 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $76.89 | 2019-2021 | |
| 180 Medical, INC. | $75.09 | 2020-2025 | Gentlecath |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corlis Archer Goode listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.